Key Highlights
- MiLaboratories secures Series A funding led by Kfund and Speedinvest.
- Launches Platforma.bio SDK, empowering biologists to analyze NGS data independently.
- Reduces reliance on bioinformaticians, accelerating drug discovery and research.
- Platforma.bio SDK is free for academic researchers to foster innovation in computational biology.
Source: Business Wire
Notable Quotes
- “We believe that opening our platform to the developer community will accelerate the adoption of modern computational tools, setting the next level of biomedical research.” — Stan Poslavsky, CEO at MiLaboratories
- “Investing in platforms that bridge the gap between developers and business users is at the core of what we want to do in our fund.” — Miguel Arias, General Partner at Kfund
SoHC's Take
MiLaboratories’ successful Series A funding and the launch of its Platforma.bio SDK mark a significant advancement in computational biology. By reducing the dependence on bioinformaticians, the Platforma.bio SDK empowers biologists to independently analyze complex genomic data, addressing long-standing bottlenecks in the field. This innovation not only accelerates research but also paves the way for faster drug discovery. The open-access model for academic researchers further supports the global research community, potentially transforming the pace of biomedical advancements. MiLaboratories is well-positioned to become a leader in this fast-growing, multi-billion-dollar market.
